Biologics for Psoriasis during the COVID-19 Pandemic
Department of Dermatology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Marcus Schmitt-Egenolf
J. Clin. Med. 2021, 10(7), 1390; https://doi.org/10.3390/jcm10071390
Received: 19 February 2021
/
Revised: 13 March 2021
/
Accepted: 28 March 2021
/
Published: 30 March 2021
(This article belongs to the Special Issue Psoriasis and Psoriatic Arthritis: How to Treat in the Era of Biologics and Small Molecule Inhibitors?)
Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19.
View Full-Text
Keywords:
psoriasis; COVID-19; SARS-CoV-2; systemic therapy; biologics
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Kamiya, K.; Komine, M.; Ohtsuki, M. Biologics for Psoriasis during the COVID-19 Pandemic. J. Clin. Med. 2021, 10, 1390. https://doi.org/10.3390/jcm10071390
AMA Style
Kamiya K, Komine M, Ohtsuki M. Biologics for Psoriasis during the COVID-19 Pandemic. Journal of Clinical Medicine. 2021; 10(7):1390. https://doi.org/10.3390/jcm10071390
Chicago/Turabian StyleKamiya, Koji, Mayumi Komine, and Mamitaro Ohtsuki. 2021. "Biologics for Psoriasis during the COVID-19 Pandemic" Journal of Clinical Medicine 10, no. 7: 1390. https://doi.org/10.3390/jcm10071390
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
